Tiny peptide · inflammation · animal studies only
A tiny peptide studied for gut and skin inflammation in cells and animals, never in people. Whether you are curious, starting, or already using it, here is what helps.

Status as of November 17, 2026. For information only, not medical advice: read the medical disclaimer.
Where are you with KPV?
Good place to start. Here is what we would want to know before deciding, in plain words.
FDA’s 2026 review found no human study, no human safety data and no case reports. So nobody knows if KPV works in people, what amount is safe, or what side effects it has.
Most studies gave KPV to mice with gut inflammation, often in drinking water or tiny carrier particles. Plain KPV taken by mouth did nothing in one 2026 mouse study.
No study of any kind has tested KPV as a nasal spray or a shot, in animals or people. In lab tests, it did not get through unbroken human skin.
KPV is not FDA approved. A 2026 US draft policy covers only skin and by-mouth KPV acetate from a pharmacy, per law-firm summaries. It is not final.
Coming Pick your questions and print them as one page.
There is no trial to lean on here. No study has given KPV to people, so nobody knows the right amount, the side effects or how long to take it. Here is what still helps.
No one has studied KPV in people, so there is no dose to point to. The amounts in animal studies are not a guide for people. Any dose question belongs with your doctor.
The calculator turns the numbers on your own label into units on a syringe. It never suggests an amount.
If you mix a powder, clean technique matters. Our step-by-step guide covers it.
Note the product name, its form and the strength on the label. Write down the symptom you hope to change, and give it a score from 0 to 10.
You’re using it. No trial has tested KPV in people, so nobody knows the right amount, the side effects or how long to take it. Here is how to keep track and stay safer.
KPV has no human evidence for any condition. It is not a swap for treatment that has been tested in people. Talk to your doctor before you change anything.
These are notes for your doctor, not a medical test.
No study has tested KPV with any other peptide, so nobody can say what a mix does.
No judgement. We won’t tell you where to buy or how much to take, but these steps lower the risk whatever you use:
KPV has no drug label and no human side-effect data, so there is no official list of warning signs. Here is what is known.
Emergency: call 911 (or your local emergency number). Possible overdose or wrong amount: Poison Help, 1-800-222-1222, free and open 24 hours. Report a bad reaction to the FDA through MedWatch.
Lists of KPV side effects on other sites, such as redness where you inject or a sore nose, cite no source. Nobody has measured them.
If you had a bad reaction, you or your doctor can report it to the FDA’s MedWatch.
Every number below says what kind of study it came from. Bracketed numbers point to the sources listed at the end.
KPV has never been given to people in a study, so there is no human time course at all. Any KPV timeline you see online has no study behind it.
What 'cell and animal only' means. Every KPV result comes from cells in a dish or from mice, rats and rabbits. These studies show why scientists are interested. They cannot tell you if KPV works in people, what amount to use, or what harm it might do.
No safety testing either. FDA found no toxicity studies of any kind, in animals or people[2]. Toxicity studies are the tests that look for harm, such as damage to genes, effects on having children, or cancer.
The form matters, and it has barely been tested. Most mouse studies put KPV in drinking water or in tiny carrier particles. Plain KPV by mouth did nothing in one 2026 mouse study[3]. In lab tests on human skin samples, KPV did not get through unbroken skin[5]. No study of any kind has tested a nasal spray or a shot.
No label. KPV has no approved drug label, so there is no official guide to storage, travel or daily use.
There are no human side-effect data, because no study has given KPV to people. FDA says the risks to people "are unknown". It flags a possible immune reaction, meaning your body's defences react to the peptide[2]. Lists of KPV side effects on other sites cite no source.
We do not show a tips list or a list of warning signs here. KPV has no drug label, and we do not make one up. If you feel unwell after any product, talk to a doctor or pharmacist and bring the product label.
This is a way to keep notes for your doctor, not a medical test.
Any dose question belongs here. No human dose has been studied, so there is no trial figure to point to[2].
What it is: the tripeptide Lys-Pro-Val, positions 11 to 13 of alpha-MSH[6]. Evidence: cell and animal only; no human data[2]. Status: not FDA approved and not on the 503A list. The HHS draft policy of 2026-10-30 covers KPV acetate for topical and oral use only, per law-firm summaries[4].
KPV reaches animal studies. No human study exists (FDA review, July 2026).
A fragment of alpha-MSH. Alpha-MSH is a 13-amino-acid hormone made from a larger precursor called POMC. KPV is its last three amino acids. According to a 2008 review, KPV keeps alpha-MSH's anti-inflammatory effect in lab models but lacks its pigment (tanning) effect[8]. Chemistry: formula C16H30N4O4, molecular weight 342.43, CAS 67727-97-3[6].
Who studies it. No company develops KPV. It is an academic research compound, studied mainly by groups in Münster, Germany, and at Emory and Georgia State in the US[8][9]. No KPV product is authorised by the EMA, and there is no European or Japanese pharmacopoeia monograph[2].
| Finding | Source | Study type |
|---|---|---|
| Nanomolar KPV blocked NF-κB and MAP kinase signalling in human gut cells and T cells | [9] | Cell |
| KPV enters cells through the PepT1 transporter, which rises in the inflamed colon | [9] | Cell |
| KPV did not raise cAMP; authors judged melanocortin receptors "unlikely" to explain its effect | [10] | Animal |
| KPV raised calcium, not cAMP, in human skin cells | [11] | Cell |
| KPV blocked NF-κB p65 from entering the nucleus in airway cells | [12] | Cell |
FDA's 2026 review concluded that the molecular targets behind KPV's effects "remain unknown" (p. 25)[2]. Many sites describe KPV as an MC1R or MC3R agonist. The primary studies and FDA's review do not support that, so the honest answer is that the mechanism is not settled.
Every study below is in animals or cells. None tells you what KPV does in people.
| Model | What was found | Source | Study type |
|---|---|---|---|
| Mouse colitis (DSS, TNBS), KPV in drinking water | Less weight loss; inflammation marker MPO down about 50% (DSS) and 30% (TNBS) | [9] | Animal |
| Mouse colitis, including mice lacking MC1R | Faster recovery, partly independent of MC1R | [13] | Animal |
| Mouse colitis, KPV in nanoparticles in a gel | Similar effect to free KPV at a 12,000-fold lower concentration | [14] | Animal |
| Mouse colitis, oral hyaluronic-acid nanoparticles | Faster gut-lining healing, lower TNF-α | [15] | Animal |
| Mouse colitis-associated cancer | Fewer tumours in normal mice; no effect in mice lacking PepT1 | [16] | Animal |
| Mouse colitis, oral prodrug study | Free KPV at 1 mg/kg by mouth showed no benefit; the prodrug did | [3] | Animal |
| Rabbit corneal scratch, eye drops | 8 of 8 treated corneas healed at 60 hours vs 0 with placebo | [17] | Animal |
| Rat mouth sores from chemotherapy, KPV gel | Better healing, lower IL-1β and TNF-α | [18] | Animal |
| Bacteria and yeast in culture | Less growth of S. aureus and C. albicans | [19] | Cell |
Gut inflammation. Most KPV research is in mouse colitis. Later papers focus on delivery systems such as nanoparticles and gels, because free KPV is poorly delivered. In one 2026 study, plain KPV by mouth did nothing in mice[3].
Skin, cornea and mouth. The skin evidence is skin cells in a dish and skin samples in a lab. In a lab test on human skin samples, KPV did not pass through intact skin at a detectable level; it only got through with microneedles[5]. The cornea and mouth results are from rabbits and rats.
Psoriasis and seborrheic dermatitis: no studies found. A PubMed search on 2026-11-17 found no study of KPV in psoriasis or seborrheic dermatitis, in people or in animals. A compounding pharmacy proposed KPV for psoriasis and eczema when it nominated it to FDA; FDA found no human data on KPV for any use[2].
No. ClinicalTrials.gov searches for KPV, Lys-Pro-Val, alpha-MSH tripeptide and KdPT on 2026-11-17 found no KPV trial. PubMed has no study that gave KPV to people. FDA's July 2026 review reached the same conclusion (pp. 20 to 26)[2]:
The closest work to people uses human cells or tissue outside the body: blood from people with HIV treated in a dish[20], skin samples in a diffusion cell[5] and a 3D skin model[21].
Amounts used in animal and cell studies (not converted). These are reported as published. They are not converted to human amounts and are not a guide for people.
| Study | Species or system | Route | Amount as published | How long | Study type |
|---|---|---|---|---|---|
| Dalmasso 2008[9] | Mouse colitis | Drinking water | 100 µM KPV in water | 8 days (DSS); 48 h (TNBS) | Animal |
| Viennois 2016[16] | Mouse colitis-associated cancer | Drinking water | 100 µmol/L KPV in water | Two 7-day DSS cycles | Animal |
| Xiao 2017[15] | Mouse colitis | By mouth, in nanoparticles | 16 µg/kg per day | 5 days | Animal |
| Cheng 2026[3] | Mouse colitis | By mouth | Free KPV 1 mg/kg (no benefit); prodrug 0.5 and 2.5 mg/kg | 7 days | Animal |
| Bonfiglio 2006[17] | Rabbit cornea | Eye drops | 1, 5 or 10 mg/mL, 4 times a day | 4 days | Animal |
| Sung 2025[21] | Human skin cells | In a dish | 50 µg/mL | 24 h | Cell |
| Dalmasso 2008[9] | Human gut cells and T cells | In a dish | Nanomolar (for example 10 nM) | Hours | Cell |
Animal and cell amounts only. Not converted, not a human dose.
We do not include community dose ranges. None of them comes from a study.
Your answer is saved only in this browser so you are not asked again. See the privacy policy.
There is no approved KPV product or label, so nothing is preset: type the mg on your own vial. Mixing steps: how to reconstitute peptides.
| Route | What has been studied | Study type | In the HHS draft policy? |
|---|---|---|---|
| Oral | Mice: drinking water and nanoparticles; free KPV at 1 mg/kg failed[3] | Animal | Yes, as KPV acetate[4] |
| Eye drops | Rabbits[17] | Animal | No |
| Skin | Did not pass through human skin samples without microneedles[5] | Cell (tissue in a lab) | Yes, as KPV acetate[4] |
| Mouth (gel) | Rats[18] | Animal | Not stated in the summaries |
| Nasal | No published study found | None | No |
| Injection | No published study found | None | No |
So for nasal or injected KPV, there is no study at all, in animals or people. The HHS draft policy is a draft, and its route details come from law-firm summaries; we have not been able to read the appendix itself.
There are no human side-effect data because no human study exists. FDA found no FAERS reports and no case reports, and says the potential risks to people "are unknown". It flags immune reactions and peptide clumping as concerns that have not been assessed (pp. 26 to 27)[2]. No toxicity study of any kind has been done.
The animal papers do not report harm in their abstracts. They were short studies of effect, not safety studies, so that is not a safety finding. Lists of KPV side effects on other sites, such as injection-site redness or nasal irritation, cite no source.
KPV is not FDA approved and is not on the 503A bulks list. A compounding pharmacy network nominated it for topical creams and gels, then withdrew the nomination (pp. 4 to 6)[2]. We have not found the date KPV was first placed in category 2.
BPC-157, TB-500, KPV and injectable GHK-Cu leave FDA category 2 because their nominators withdrew them. Leaving the list does not make them legal to compound.
Frier Levitt summary of the FDA notice[22] RegulatorFDA's safety page lists KPV as "nominated but withdrawn" and says FDA has not identified any human exposure data for KPV by any route.
FDA safety-risk page[23] RegulatorFDA staff propose that neither KPV free base nor KPV acetate be added to the 503A list: poorly characterised, unknown extent of use, no human data.
FDA briefing documents for the advisory committee[24] RegulatorFDA advisory committee votes 8-6-1 to recommend BPC-157, KPV and TB-500 for the 503A list, against FDA staff advice. The vote is advisory.
McDermott summary of the meeting[7] RegulatorHHS publishes a draft enforcement-discretion policy for compounding certain peptides. Per law-firm summaries, KPV is covered as KPV acetate, topical and oral only, single-ingredient products only.
Federal Register 91 FR 68526; McDermott summary of Appendix A[25] RegulatorCan a pharmacy compound KPV in 2026? The HHS policy is a draft. Its comment period closed about two weeks after publication, and we will update this page if a final version is issued. Per law-firm summaries[4], it covers only topical and oral KPV acetate in single-ingredient products. Injected and nasal KPV are outside it. We found no FDA warning letter or import alert naming KPV, though our search was not exhaustive.
Sport (WADA). KPV is not named on the WADA Prohibited List[26]. The S0 catch-all for substances without government approval for human therapeutic use probably applies. That is our reading, not a WADA ruling; athletes should check with their anti-doping body. A 2026 review lists KPV among peptides used in sport[27].
No published study has tested KPV with CJC-1295, ipamorelin, GHK-Cu, Melanotan 1 or any other peptide. FDA notes that clinics promote KPV in multi-peptide "regenerative" combinations (p. 19)[2]. Per law-firm summaries, the HHS draft policy covers only single-ingredient products, so a compounded mix that includes KPV falls outside it.
KPV is one of four peptides in the KLOW blend, alongside GHK-Cu, BPC-157 and TB-500.
Direct answers to what people search for. Bracketed numbers point to the sources at the end; the sections above have the detail.
A tiny peptide of three amino acids, taken from the end of the hormone alpha-MSH. In lab models it keeps the hormone's effect on inflammation but not its tanning effect[8].
No. FDA's July 2026 review found no human studies, no data on how the body handles it and no case reports[2].
No. It is not approved and is not on FDA’s 503A list. An FDA advisory group voted to recommend adding it, but that vote does not decide anything.
Only in some forms, and only under a draft. Law-firm summaries say the HHS draft from October 2026 covers KPV acetate as a skin or by-mouth product with one active part[4]. It is not final yet.
No one knows. No study of KPV in either condition has been published, in people or animals (PubMed, 2026-11-17).
None of these has been tested in people. By mouth was tested in mice only, and plain KPV failed in one 2026 study. No nasal or injected study exists.
There is no data. No study has tested KPV with any of them.
It is not named on the WADA list. But WADA’s S0 rule for unapproved substances probably covers it. Check with your anti-doping body.